PharmPK Discussion List Archive - 2014

PharmPK Discussion List Frequently Discussed Topics

Acetaldehyde determination in blood or plasma
Algebraic expression
Analyzing sparse tissue sample data
BA/BE Creams and Injections
BACs after drinking beer, wine and spirits
BCS Classification
BCS of Clonixin
Bioavailability and Clearance
Bioavailability calculation - mean ratio
Bioequivalence assessment at steady state
Blank samples
Calculating AUCinf with increasing concentrations in the end
Calculating dose normalized AUC
Changes in metabolism with slow release formulations
Ciprofloxacin metabolism
Concentrations above upper limit of quantification
Cortisone concentration in rat plasma
Creating subsets of xpdb objects in XPOSE
Cross over design - 2 groups
Day 7 cut off plasma concentrations for antimalarial drugs
DCGI permission for the BE study on patients
Different stripping methods for plasma
Dissolution modelling
Drug in breast milk pharmacokinetics
Electronic notebook for Academic lab use
Emesis criteria for multiple dose study
Encoding IV infusion+multiple bolus for MONOLIX
Enteroheptic recycling without excretion
Estimation of the absorption rate constant
Food effect morning after evening administration MR formulation
Formulation for dog studies (IV/PO)
Free drug concentration in tissue
Hepatocellularity in pig
Herb-drug PK Interaction
How to choose the data near LLOQ
How to model nonlinear pharmacokinetics
How to test effect of treatment on PK parameters
Immunosuppressive Drugs - Trademark Combination in Transplant
In vitro metabolism of cytarabine
In vitro skin permeability
Incorporate sustained release granule and lozenges tablet
Incremental Loading dose
Incubation time in PAMPA assay
Individualized drug therapy and the pharmaceutical industry
Initial estimate of ke0 in PK/PD Link Model
Low drug concentration level in PO admin
Low excretion and high distribution in tissues
Low volume blood stabilizer
Means and means
Metabolism study
Mouse to human dose
MSE Calculation
Nicotine LC-MSMS method development
Non Linear Covariate Analysis in Phoenix NLME
P-glycoprotein
PBPK model by Peng et al 2001
Pharmacokinetics of Progesterone
PK calculation when the drug itself is the endogenous substance
PK of mAB in mice
PK-Sim/MoBi users
PK/PD Modelling _Feedback model
Plasma protein binding and Free drug
Population PK/PD modeling in general
Pregnancy and BBB permeability
Prodrug/metabolite and IVIVC
Rapamycin PK in rats
Reference scaled BE study
Releasing BLQ datapoints
Renal CL of carboxylic acids in dogs
Reporting half-life
Sample Size
Saturation in Calibration Curve
Single point PK estimation
Smooth in bioanalysis
Software ELSNER
Software for urinary kinetics
Standard deviations for pk parameter estimates
Study design question for Long half-life CYP 3A4 substrate in a drug-drug interaction
Study design question for Long half-life CYP 3A4 substrate in a drug-drug interaction study
Survival analysis in Pharmacokinetics
Transporter in vitro studies vs clinical conc.
Vss estimation from effective half life
Weighting in the terminal phase estimation in NCA
WFN for NONMEM 7.3.0 - version 735
WinNonlin - Fixed AUC Cmax simulation
Zero as a Standard Point

Visit the PharmPK Website for more information